Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerardo Maradiaga

Internal Medicine Roanoke Rapids, NC Medical Doctor

NPI 1841361367 CMS profile 174808

270 Smith Church Road, Roanoke Rapids, NC 27870

Open in the dashboard

General payments

$5,090

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gerardo Maradiaga of Roanoke Rapids, NC is reported in the CMS Open Payments database as having received $5,090 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $665 27
2024 General $353 16
2023 General $310 16
2022 General $75 5
2021 General $571 32
2020 General $1,434 92
2019 General $1,683 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerardo Maradiaga
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gerardo Maradiaga were reported at $665. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gerardo Maradiaga Internal Medicine median Middle half National median
2019 $1,683 $159 $48–$570 $163
2020 $1,434 $119 $33–$402 $114
2021 $571 $135 $37–$521 $132
2022 $75 $141 $42–$496 $149
2023 $310 $149 $45–$519 $160
2024 $353 $154 $47–$537 $164
2025 $665 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,069 79 payments
  2. AstraZeneca Pharmaceuticals LP $1,015 38 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $655 44 payments
  4. Sanofi-Aventis U.S. LLC $492 34 payments
  5. Amgen Inc. $486 32 payments
  6. AbbVie, Inc. $226 14 payments
  7. Lilly USA, LLC $211 14 payments
  8. Corcept Therapeutics $163 4 payments
  9. GlaxoSmithKline, LLC. $134 9 payments
  10. Horizon Therapeutics plc $86 6 payments
  11. Other $552 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,090 310 payments
Products named General payments · program years 2019–2025
  1. Ozempic $691 58 payments
  2. FARXIGA $629 19 payments
  3. JARDIANCE $522 33 payments
  4. RYBELSUS $431 32 payments
  5. Repatha $296 19 payments
  6. AIMOVIG $212 13 payments
  7. SYMBICORT $207 5 payments
  8. BEVESPI AEROSPHERE $188 7 payments
  9. SOLIQUA 100/33 $177 12 payments
  10. AIRSUPRA $168 4 payments
  11. Other $3,467 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 215 drugs

Part D claims

17,331

Median for Internal Medicine: 777

Drug cost

$1,232,144

Median for Internal Medicine: $73,373

Branded share of claims

20%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 201 $151,303
Ozempic Semaglutide Brand 141 $129,797
Xarelto Rivaroxaban Brand 107 $121,134
Jardiance Empagliflozin Brand 144 $119,526
Rybelsus Semaglutide Brand 50 $69,770
Mounjaro Tirzepatide Brand 46 $54,266
Invokana Canagliflozin Brand 61 $51,631
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 59 $43,640
Tresiba Flextouch U-200 Insulin Degludec Brand 40 $31,168
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $28,213

The 10 drugs with the highest cost, of 215 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$3,722

Medicare's payments for the services billed

Medicare patients

143

Average age 76

Services billed

215

84 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 57%
Ischemic heart disease 44%
Chronic kidney disease 41%
Atrial fibrillation 27%
Depression 27%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $102
$102 19 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $33
  • Lilly USA, LLC $16
$49 144 —
QULIPTA
  • AbbVie, Inc. $41
$41 — —
Korlym
  • Corcept Therapeutics $33
$33 — —
Otezla
  • Amgen Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record